Guilt by association? Examining the role of bisphosphonate therapy in the development of atypical femur fractures

Bone

Volumn 48, Issue 5, 2011, Pages 963-965

  Girgis, Christian M ^a,b   Seibel, Markus J ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PLACEBO; RISEDRONIC ACID;

BONE DENSITY; BONE INJURY; BONE REMODELING; BONE TURNOVER; CASE CONTROL STUDY; DISEASE ASSOCIATION; DOG; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FEMUR FRACTURE; FEMUR SHAFT FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FRAGILITY FRACTURE; HUMAN; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NONHUMAN; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMATIC ERROR; TREATMENT DURATION; VERTEBRA FRACTURE;

ANIMALS; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; DOGS; FEMORAL FRACTURES; HUMANS; OSTEOPOROSIS; RISK FACTORS;

EID: 79954601351     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.02.013     Document Type: Editorial

References (33)

1. Johnell O., Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006, 17(12):1726-1733.
2. Siris E.S., Pasquale M.K., Wang Y., Watts N.B. Estimating bisphosphonate use and fracture reduction among US women aged 45years and older, 2001-2008. J Bone Miner Res 2011, 26(1):3-11.
3. Cranney A., Wells G., Willan A., Griffith L., Zytaruk N., Robinson V., et al. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002, 23:508-516.
4. Cranney A., Tugwell P., Adachi J., Weaver B., Zytaruk N., Papaioannou A., et al. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002, 23:517-523.
5. Lyles K.W., Colón-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
6. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal Osteoporosis. N Engl J Med 2007, 356:1809-1822.
7. Dunstan C.R., Felsenberg D., Seibel M.J. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 2007, 4:42-55.
8. Lenart B.A., Lorich D.G., Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008, 358:1304-1306.
9. Giusti A., Hamdy N.A.T., Papapoulos S.E. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010, 47:169-180.
10. Lee P., van der Wall H., Seibel M.J. Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 2007, 30:590-597.
11. Girgis C.M., Sher D., Seibel M.J. Atypical femoral fractures and bisphosphonate use. N Engl J Med 2010, 362:1848-1849.
12. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095-1102.
13. Abrahamsen B., Eiken P. Eastell R Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010, 95(12):5258-5265.
14. Black D., Kelly M., Genant H., Palermo L., Eastell R., Bucci-Rechtweg C., et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010, 362:1761-1771.
15. Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., Lorich D.G. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008, 22:346-350.
16. Kwek E.B., Goh S.K., Koh J.S., Png M.A., Howe T.S. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury 2008, 39:224-231.
17. Nieves J.W., Bilezikian J.P., Lane J.M., Einhorn T.A., Wang Y., Steinbuch M., et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2010, 21:399-408.
18. Dell R, Greene D, Ott S, Silverman S, Eisemon E, Funahashi T, et al. A retrospective analysis of atypical femur fractures in a large California HMO from the years 2007 to 2009 (Abstract 1201; ASBMR Meeting 2010, Toronto).
19. Vestergaard P., Schwartz F., Rejnmark L., Mosekilde L. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int 2011, 22:993-1001.
20. Giusti A, Hamdy NAT, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE. Atypical fractures and bisphosphonate therapy: A cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features Bone, in press, Available online 31 December 2010.
21. Lenart B.A., Neviaser A.S., Lyman S., Chang C.C., Edobor-Osula F., Steele B., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20:1353-1362.
22. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., Pak C.Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
23. Boskey A, Lane JM, Rebolledo B, Gladnick B, Meredith D, Donnelly E. Reduced matrix heterogeneity with bisphosphonate treatment in postmenopausal women with proximal femoral fractures (Abstract 1140, ASBMR Meeting 2010, Toronto).
24. Somford M.P., Draijer F.W., Thomassen B.J., Chavassieux P.M., Boivin G., Papapoulos S.E. Bilateral fractures of the femoral diaphysis in a patient with rheumatoid arthritis on long term treatment with alendronate. J Bone Miner Res 2009, 24:1736-1740.
25. Recker R., Ensrud K., Diem S., Cheng E., Bare S., Masarachia P., et al. Normal bone histomorphometry and 3D microarchitecture after 10years alendronate treatment of postmenopausal women. J Bone Miner Res 2004, 19(suppl 1):S45.
26. Ste-Marie L.G., Sod E., Johnson T., Chines A. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 75:469-476.
27. Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quandt S.A., et al. Effects of continuing or stopping alendronate after 5years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296:2927-2938.
28. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy Study Group. JAMA 1999, 282:1344-1352.
29. Mashiba T., Hirano T., Turner C.H., Forwood M., Johnston C.C., Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15:613-620.
30. Forwood M.R., Burr D.B., Takano Y., Eastman D.F., Smith P.N., Schwardt J.D. Risedronate treatment does not increase microdamage in the canine femoral neck. Bone 1995, 16:643-650.
31. Allen M.R., Iwata K., Phipps R., Burr D.B. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006, 39:872-879.
32. Shane E., Burr D., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research Running title: Atypical Femoral Fractures Task Force Report. J Bone Miner Res 2010, 25:2267-2294.
33. Rizzoli R., Akesson K., Bouxsein M., Kanis J.A., Napoli N., Papapoulos S., et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011, 22:373-390.